Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The London-based pharmaceutical company said Japan's Ministry of Health, Labour and Welfare has accepted the application to review its Blenrep antibody drug in combination with BorDex or PomDex as a ...